感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议已即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 大家好欢迎参加脉锐医疗2024年三季度预计电话会本次会议语言为中文和英文同传如需接听英文频道请联系汇丰前海或脉锐投观团队 下面开始播报免责声明本次电话会议仅服务于华创证券研究所和汇丰前海客户不构成投资建议相关人员应自主作出投资决策并自行承担投资风险华创证券和汇丰前海不对应使用本次内容所导致的任何损失承担任何责任专家发言内容仅代表专家个人观点 不代表本公司观点本次会议内容不得涉及国家保密信息内幕信息未公开重大信息商业秘密个人隐私不得涉及可能引发不当炒作或股价异常波动的敏感信息 不得涉及影响社会或资本市场稳定的言论未经华创证券和汇丰前海事先书面许可任何机构或个人不得以任何形式复制、刊载、转载、转发、引用本次会议内容否则由此造成的一切后果及法律责任由该机构或个人承担 华创证券和汇丰全海保留追究其法律责任的权利市场没有风险投资需谨慎下面有请主持 ...

公 司 报 告 公 司 季 报 点 评 证 券 研 究 报 告 迈瑞医疗(300760.SZ) 国内增长承压，海外表现亮眼 推荐 ( 维持) 事项： 股价:271.24元 主要数据 | --- | --- | |------------------------|-----------------------| | 行业 | 医药 | | 公司网址 | www.mindray.com | | 大股东 / 持股 | Smartco Development | | | Limited/26.98% | | 实际控制人 | 李西廷 , 徐航 | | 总股本 ( 百万股 ) | 1,212 | | 流通 A 股 ( 百万股 ) | 1,212 | | 流通 B/H 股 ( 百万股 ) | | | 总市值 ( 亿元 ) | 3,289 | | 流通 A 股市值 ( 亿元 ) | 3,289 | | 每股净资产 ( 元 ) | 30.59 | | 资产负债率 (%) | 27.1 | | 行情走势图 | | 证券分析师 | --- | |--------------------------| | | | 投资咨询资格编号 ...

来源：公司年报、国金证券研究所 迈瑞医疗 (300760.SZ) 买入(维持评级) 业绩简述 2024 年 10 月 29 日，公司发布 2024 年三季度报告：2024 年前三 季度公司实现收入 294.85 亿元，同比+8%；归母净利润 106.37 亿 元，同比+8%；实现扣非归母净利润 104.37 亿元，同比+8%； 2024Q3 公司实现收入 89.54 亿元，同比+1%；归母净利润 30.76 亿 元，同比-9%；实现扣非归母净利润 30.57 亿元，同比-9%。 经营分析 国际市场增长亮眼，体外诊断成为增长支撑。受益于海外高端战 略客户和中大样本量实验室的持续突破以及种子业务的放量，公 司国际市场前三季度增长超过 18%，其中欧洲和亚太市场增长均超 过了 30%。国内市场由于招标需求推迟等因素，前三季度增长不到 2%。体外诊断产线前三季度增长超过 20%，受益于加速推动海外本 地化生产和中大样本量实验室突破，国际体外诊断产线增长超过 30%，国内化学发光、生化、凝血等业务的市占率稳步提升。 保持高研发投入，取得众多阶段性创新成果。公司前三季度研发 投入达到 28.43 亿元，占营业收入比重 9 ...

Financial Performance - Revenue for the third quarter was 8,954,208,694 RMB, a 1.43% increase year-over-year[2] - Net profit attributable to shareholders for the third quarter was 3,076,337,561 RMB, a 9.31% decrease year-over-year[2] - Cumulative revenue from the beginning of the year to the end of the reporting period was 29,484,805,493 RMB, a 7.99% increase year-over-year[2] - Cumulative net profit attributable to shareholders from the beginning of the year to the end of the reporting period was 10,637,075,305 RMB, an 8.16% increase year-over-year[2] - Revenue for the first three quarters of 2024 reached 294.85 billion yuan, a year-on-year increase of 7.99%[12] - Net profit attributable to shareholders was 106.37 billion yuan, a year-on-year increase of 8.16%[12] - Total revenue for the current period reached 29.48 billion yuan, an increase from 27.30 billion yuan in the previous period[20] - Net profit attributable to the parent company increased to 28.58 billion yuan from 24.68 billion yuan in the previous period[19] - Net profit attributable to parent company shareholders reached RMB 10.637 billion, an increase from RMB 9.834 billion in the previous period[21] - Basic earnings per share increased to RMB 8.7808, up from RMB 8.1216 in the previous period[21] - Comprehensive income attributable to parent company shareholders was RMB 10.564 billion, compared to RMB 10.033 billion in the previous period[21] Cash Flow and Financial Position - Operating cash flow for the period increased by 42.50% year-over-year, reaching 11,072,880,996 RMB[2][6] - Total assets at the end of the reporting period were 57,601,486,436 RMB, a 20.15% increase compared to the end of the previous year[2] - Shareholders' equity attributable to the company at the end of the reporting period was 37,093,899,069 RMB, a 12.12% increase compared to the end of the previous year[2] - Total assets increased to 57.60 billion yuan from 47.94 billion yuan in the previous period[19] - Total liabilities increased to 15.59 billion yuan from 14.59 billion yuan in the previous period[18] - Total equity increased to 42.01 billion yuan from 33.35 billion yuan in the previous period[19] - Operating cash flow increased to RMB 11.073 billion, up from RMB 7.771 billion in the previous period[22] - Cash and cash equivalents at the end of the period decreased to RMB 15.583 billion from RMB 18.668 billion at the beginning of the period[23] - Tax refunds received increased to RMB 866.82 million, up from RMB 769.52 million in the previous period[22] - Payments for employee benefits and wages increased to RMB 6.429 billion, compared to RMB 5.649 billion in the previous period[22] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period is 72,917[8] - Smartco Development Limited holds 26.98% of the shares, totaling 327,072,335 shares[8] - Magnifice (HK) Limited holds 24.49% of the shares, totaling 296,951,000 shares, with 36,820,000 shares pledged[8] - Hong Kong Securities Clearing Company Limited holds 12.01% of the shares, totaling 145,616,297 shares[8] - Ever Union (H.K.) Limited holds 4.25% of the shares, totaling 51,482,379 shares[8] - The China Industrial and Commercial Bank Limited - E Fund ChiNext ETF holds 1.20% of the shares, totaling 14,541,569 shares[8] - The China Industrial and Commercial Bank Limited - Huatai-PineBridge CSI 300 ETF holds 0.95% of the shares, totaling 11,520,049 shares[8] - Shenzhen Ruifu Management Consulting Partnership holds 0.86% of the shares, totaling 10,405,351 shares[8] - The China Industrial and Commercial Bank Limited - China Europe Healthcare Hybrid Fund holds 0.84% of the shares, totaling 10,183,344 shares[8] - Shenzhen Ruilong Consulting Services Partnership holds 0.84% of the shares, totaling 10,156,738 shares[8] Market and Product Performance - International market revenue grew by over 18%, with Europe and Asia-Pacific markets growing by more than 30%[12] - Domestic market revenue grew by less than 2% due to delayed hospital procurement and tight construction funds[12] - In vitro diagnostics product line grew by over 20%, with international in vitro diagnostics growing by over 30%[12] - Medical imaging product line grew by over 10%, driven by the Resona A20 ultrasound system[12] - Life information and support product line declined by over 10%, with domestic sales dropping by more than 20%[12] Research and Development - R&D investment in the first three quarters of 2024 was 28.43 billion yuan, accounting for 9.64% of revenue[13] - The company launched 10 new chemical luminescence immunoassay reagents and 10 biochemical analysis reagents in Q3 2024[13] - Cumulative patent applications reached 11,358, with 8,115 invention patents and 5,563 authorized patents[13] - R&D expenses increased to 2.59 billion yuan from 2.51 billion yuan in the previous period[20] Operational Costs and Liabilities - Operating costs for the current period were 17.87 billion yuan, up from 16.55 billion yuan in the previous period[20] - Inventory increased to 4.86 billion yuan from 3.98 billion yuan in the previous period[17] - Accounts receivable increased to 3.60 billion yuan from 3.30 billion yuan in the previous period[17] - Short-term borrowings decreased to 5.68 million yuan from 7.75 million yuan in the previous period[18] - Investment cash outflow was RMB 7.962 billion, a significant increase from RMB 5.910 billion in the previous period[22] - Financing cash outflow was RMB 6.969 billion, compared to RMB 5.593 billion in the previous period[23] Earnings and Shareholder Returns - Basic earnings per share for the third quarter were 2.5364 RMB, a 9.50% decrease year-over-year[2] - Weighted average return on equity for the third quarter was 7.93%, a decrease of 1.72 percentage points year-over-year[2] - Non-recurring gains and losses for the third quarter amounted to 19,324,724 RMB[4] - Sales revenue from goods and services reached RMB 31.578 billion, compared to RMB 26.496 billion in the previous period[22]

迈瑞医疗：第三季度净利润30.76亿元 同比下降9.31% 财联社10月29日电，迈瑞医疗发布2024年第三季 度报告，前三季度公司实现营业收入294.85亿元，同比增长7.99%；净利润106.37亿元，同比增长 8.16%。 其中，第三季度实现营业收入89.54亿元，同比增长1.43%；净利润30.76亿元，同比下降9.31%。 查看公告原文 ...

深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 证券代码：300760 证券简称：迈瑞医疗 编号：2024-007 深圳迈瑞生物医疗电子股份有限公司 | --- | --- | --- | |--------------------------|-----------------------------------------------------|------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n 业绩说明会 \n | | | □其他 | | | 参与单位名 称及人员姓 名 | 线上参与公司 2024 | 年半年度网上业绩说明会的全体投资者 | | 时间 | 2024 年 9 月 14 日 | | | 地点 | 价值在线（ https://www.ir-online.cn/ | ）网络互动 | | | | | | | 董事长 李西廷 | | | | | | | 上市公司接 | 财务负责人 赵云 | | | | 董事兼总经理 吴昊 | | | 待人员姓名 ...

丨证券研究报告丨 公司研究丨点评报告丨迈瑞医疗（300760.SZ） [Table_Title] 业绩高质量增长，深耕数智化 | --- | --- | |------------------------------------------------------------------------------------------------------------------|-------| | 报告要点 | | | [Table_Summary] 公司业绩增长稳健， 2024 年上半年营业收入为 205.3 亿元，同比增长 11.1% ，主要是受到医疗 | | | 行业整顿和设备更新正常影响，招采活动普遍处于观望状态有所延迟，预计下半年有望逐步恢 | | | 复。深耕海外市场，持续突破高端客户： 2024 年上半年公司海外收入 79.1 亿元，同比增长 | | | 18.1% ，占总收入的比重为 39% ；其中欧洲收入 15.0 亿元，同比增长 37.9% 。深耕"设备 +IT+AI" | | | 的智能医疗生态系统的搭建：公司的"三瑞"数智化方案过去三年实现的累计销售额、以及带 | | | 动的设 ...

证 券 研 究 报 告 迈瑞医疗（300760）2024 年中报点评 推荐（维持） 业绩增长稳健，IVD 业务表现突出 目标价：335 元 当前价：231.67 元 | --- | --- | --- | --- | --- | --- | |-------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------- ...

迈瑞医疗（300760.SZ）深度报告 医械龙头三十载，乘风破浪正当时 2024 年 09 月 12 日 | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

[ T able_StockInfo] 2024 年 09 月 03 日 证券研究报告•2024 年中报点评 买入 （维持） 当前价：247.49 元 迈瑞医疗（300760）医药生物 目标价：——元（6 个月） 24H1 业绩符合预期，IVD 业务持续高增 [Table_Summary 事件：公司发布] 2024年中报，公司实现营业收入 205.3亿元（+11.1%），实现 归母净利润 75.6 亿元（+17.4%），实现扣非归母净利润 73.8 亿元（+16.4%） 其中 24Q2营业收入 111.6亿元（+10.4%），归母净利润 44亿元（+13.7%）扣 非归母净利润 43.4 亿元（+13.9%）。 24H1业绩符合预期，IVD业务持续高增。分季度看，2024Q1/Q2单季度收入 9 3.7/111.58亿元（+12.1%/+10.3%），单季度归母净利润分别为 31.6/44亿元（+ 22.9%/+13.7%）。从盈利能力看，24H1毛利率 66.3%（+0.65pp）。销售费用率、 管理费用率、研发费用率、财务费用率分别为 14.3%（-1.04pp）、4%（-0.3pp）、 8.6%（-1. ...